lar access survival was significantly lower in patients with high plasma fibrinogen levels (Á460 mg/dl ) comBackground. Elevated plasma fibrinogen is an important risk factor for coronary artery disease in the general pared with patients with low levels (<460 mg/dl ) (P= 0.007). Independent risk factors for vascular access population and patients with chronic renal failure. High plasma fibrinogen may trigger thrombus forma-failure analysed by Cox's proportional hazards model were older age (RR; 1.36 by 10-year increment), higher tion in arteriovenous fistulas. We performed a prospective, cohort study to evaluate the association of plasma fibrinogen level (RR; 1.20 by 100 mg/dl increment), PTFE graft (RR; 2.28) and r-HuEPO therapy (RR; fibrinogen concentration with vascular access failure in patients undergoing long-term haemodialysis.
In Suk Song et al. 138 [5] and recurrent [6 ] coronary artery disease in the Results general population, for vascular complications in diabetes [7] and for atherosclerotic cardiovascular dis-The baseline characteristics of the patients are shown ease in chronic renal failure patients [8] . In the presence in Table 1 . The median age of the patients was 52 of low fibrinogen concentrations, the risk of coronary years (range; 19-78 years). The median duration of events remained low even in patients with high serum haemodialysis was 37 months (range; 18-102 months). cholesterol levels [9] . High plasma fibrinogen may also In 35 patients (34%), renal disease was secondary to serve as a trigger for thrombus formation in arterio-diabetes mellitus. A PTFE graft served as vascular venous fistulas. However, little has been evaluated access in 17 patients (17%). Seventy-seven patients regarding the relationship between the level of plasma (76%) received r-HuEPO therapy. Thirty-eight patients fibrinogen and the occurrence of vascular access failure. had at least one vascular access failure during the We performed a prospective cohort study to evaluate follow-up period, and the frequency of vascular access the association of plasma fibrinogen concentration failure was 0.3 episodes per patient-year (range; 0-2.4). with vascular access failure in patients undergoing Vascular access survival was 78% (native fistula; 80%, long-term haemodialysis. PTFE graft; 71%) after 12 months and 70% (native fistula; 73%, PTFE graft; 51%) after 24 months.
Comparisons of clinical and biochemical data of
Subjects and methods
patients with and without vascular access failure are shown in Table 2 . Older age, a PTFE graft, r-HuEPO This prospective cohort study was initiated at Asan Medical therapy, higher hematocrit, lower albumin and higher Center in September 1989. Patients with end-stage renal fibrinogen levels were significantly associated with disease ( ESRD) were eligible for entry into the study if they vascular access failure, whereas gender, diabetes melunderwent a vascular access operation at our center and litus, total cholesterol and platelet count were not. survived for more than 3 months. One-hundred and forty-Comparisons of clinical and biochemical data accordfour patients were enrolled until October 1995. Forty-two ing to fibrinogen level are shown in Table 3 . In patients patients were excluded for the following reasons: 26 patients with high plasma fibrinogen levels (Á460 mg/dl ), received renal transplants, three patients switched to peritonserum albumin was lower and vascular access failure eal dialysis and 13 patients expired. The remaining 102 patients (70.8% of enrollment) were followed for more than fibrinogen levels (Á460 mg/dl ) and those with low levels (<460 mg/dl ) were obtained by the Kaplan-Meier method and compared using a log-rank test.
*Median. of a PTFE graft (32.3-39.9%) is about twice that of a native fistula (14.4-18.4%) during 12 months of followwas higher. Plasma fibrinogen was inversely correlated up after arteriovenous fistula surgery. After follow-up with serum albumin (r=−0.38, P=0.001). Figure 1 
[13] also to fibrinogen level. The cumulative vascular access reported that old age and PTFE graft were associated survival was significantly lower in patients with high with increased arteriovenous fistula thrombosis. plasma fibrinogen levels (Á460 mg/dl ) than in patients Considering that the PTFE grafts were usually placed with low levels (<460 mg/dl ). A fibrinogen level of in those with failed arteriovenous fistula or with poor 460 mg/dl proved to be the cut-off point with the most arteries and veins, it is not surprising that a PTFE predictive value (sensitivity; 61%, specificity; 67%). graft was a risk factor for vascular access failure. Independent risk factors of vascular access failure r-HuEPO may cause thrombosis by increasing haemanalyzed by the Cox's proportional hazards model atocrit and blood viscosity, altering haemostasis and were older age, higher fibrinogen level, a PTFE graft enhancing platelet function [15] . Results of studies and r-HuEPO therapy ( Table 4) .
regarding the association of increased vascular access failure with r-HuEPO therapy have been inconsistent. Besarab et al.
[12] investigated the rate of thrombotic events in 164 dialysis patients receiving r-HuEPO for more than 2 months and were unable to detect any evidence of increased frequency of thrombosis either for a PTFE graft or for a native fistula. On the contrary, Dy et al.
[16 ] performed a cohort study of 46 dialysis patients before and after treatment with r-HuEPO for 12 months and reported a greater incidence of graft thrombosis in the r-HuEPO period. A similar finding was also reported by the Canadian Erythropoietin Study [17] . The result of the present study is in agreement with the latter studies. In the study by Besarab et al.
[12], r-HuEPO was given for a longer duration than in the present study. Thus, it may be possible that prolonged administration of fistula.
Several reports found diabetes to be associated with inadequate native arteriovenous fistula (100 vs 17%) than the present study. Tang et al. [19] reported that *Analysed by 10 year increment, †analyzed by 100 mg/dl increment.
In Suk Song et al. 140
although vascular access failure occurred more fre-vivo studies have shown that the addition of albumin blunted the stimulatory effect of free fatty acids which quently in diabetic patients, it was more prevalent with a PTFE graft than a native fistula (65 vs 20%), even stimulated hepatic synthesis of fibrinogen. Decrease in serum albumin, therefore, may stimulate the producin diabetic patients. In the report by Goldwasser et al.
[13], diabetes was associated with vascular access tion of fibrinogen in the liver [26 ] . The elevated plasma fibrinogen in turn, may contribute to the formation of failure with a univariate analysis, but was not an independent risk factor with a multivariate analysis. thrombi in the vascular access.
In summary, we have prospectively evaluated the Thus, the increased incidence of vascular access failure in diabetic patients may depend on the presence of influence of plasma fibrinogen on vascular access failure in patients undergoing long-term haemodialysis. confounding variables, such as age and the use of a PTFE graft.
Our study showed that plasma fibrinogen is an independent risk factor for vascular access failure in To our knowledge, there has been only one study evaluating fibrinogen as a risk factor for vascular haemodialysis patients. access failure. The study by de Marchi et al. [20] evaluated 30 non-diabetic patients with a native fistula Acknowledgements. This study was supported by a grant from the and fibrinogen was not found to be a risk factor for Ministry of Health and Welfare (97-0278, Park JS). fistula dysfunction. However, we found very high fibrinogen levels to be an independent risk factor for vascular access failure in our present study which had References a larger number of patients, including those with a [24, 25] , which in turn may increase the risk for clotting. 
